Future of Aventis CropScience s Genomics Activities Uncertain in Light of Possible Sale to Bayer | GenomeWeb

LYON, France, July 12 – An Aventis executive said Thursday it was too early to speculate about how the proposed sale of Aventis CropScience to Bayer would impact the company’s genomics efforts.

“I don’t know if there will be any effect; it’s too early to tell,” Georges Freyssinet, head of global genomic research at CropScience, told GenomeWeb.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.